Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIp Group Regulatory News (IPO)

Share Price Information for Ip Group (IPO)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 50.20
Bid: 49.90
Ask: 50.20
Change: 1.60 (3.29%)
Spread: 0.30 (0.601%)
Open: 48.45
High: 51.10
Low: 47.20
Prev. Close: 48.60
IPO Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Oxford Nanopore funding round and contract win

13 Oct 2020 07:00

RNS Number : 8541B
IP Group PLC
13 October 2020
 

FOR RELEASE ON

13 October 2020

 

 

IP Group plc - Portfolio company Oxford Nanopore Technologies announces £84.4m of additional funding

 

IP Group plc (LSE: IPO) ("IP Group" or "the Group"), the developer of intellectual property-based businesses, notes that its portfolio company Oxford Nanopore Technologies Ltd ("Oxford Nanopore" or "the Company") has announced that it has raised an additional £84.4 million of new capital from existing and new investors including International Holdings Company (IHC) and RPMI Railpen.

 

The funds will be used to support the rapid acceleration of Oxford Nanopore's commercial and manufacturing operations as well as ongoing innovation in the field of nanopore technology. The round takes the amount raised this year by Oxford Nanopore to £162.1 million, following fund raisings in January and May of £29.3 million and £48.4 million respectively.

 

Following the capital raise, IP Group has a 15.0% undiluted beneficial stake in Oxford Nanopore, valued at £257.7 million. The directors will review the carrying value of Oxford Nanopore, as usual, as part of the Group's Annual Results for 2020 in light of this funding round and all other relevant information.

 

Last week, Oxford Nanopore announced that its LamPORE test is now CE marked for in vitro diagnostic use for the detection of the SARS-CoV-2 virus that causes COVID-19, using its GridION device. Its LamPORE test is now in the process of initial rollouts in the UK, Germany, Switzerland and the United Arab Emirates.

 

The Company previously announced that it had partnered with the UK's Department of Health and Social Care with an initial order of 450,000 LamPORE SARS-CoV-2 tests and the potential to increase to millions of tests per month as indicated by the recent publication of a contract award notice of £112.6m on the TED (Tenders Electronic Daily) website. Further regulatory approvals are being pursued in other countries, including Emergency Use Authorisation in the United States, and with its partner G42 in the United Arab Emirates.

 

For more information, please contact:

 

IP Group plc

www.ipgroupplc.com

Greg Smith, Chief Financial OfficerLiz Vaughan-Adams, Communications

+44 (0) 20 7444 0050+44 (0) 20 7444 0062/+44 (0) 7979 853802

Charlotte Street Partners

David Gaffney

+44 (0) 7854 609998

Andrew Wilson

+44 (0) 7810 636995

 

Notes for editors

 

About IP Group

 

IP Group is a leading intellectual property commercialisation company which focuses on evolving great ideas, mainly from its partner universities, into world-changing businesses. The Group has pioneered a unique approach to developing these ideas and the resulting businesses by providing access to business building expertise, capital (through its 100%-owned FCA-authorised subsidiaries IP Capital and Parkwalk Advisors), networks, recruitment and business support. IP Group has a strong track record of success and its portfolio comprises holdings in early-stage to mature businesses across life sciences and technology. IP Group is listed on the Main Market of the London Stock Exchange under the code IPO.

 

Group holdings in portfolio companies reflect the undiluted beneficial equity interest excluding debt, unless otherwise explicitly stated.

 

For more information, please visit our website at www.ipgroupplc.com.

 

ENDS

 

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NRAGPGQPUUPUPGP
Date   Source Headline
13th Jan 20227:00 amRNSPre-closed-period update
12th Jan 20226:06 pmRNSTransaction in Own Shares
11th Jan 20225:26 pmRNSTransaction in Own Shares
10th Jan 20226:11 pmRNSTransaction in Own Shares
7th Jan 20225:38 pmRNSTransaction in Own Shares
6th Jan 20225:20 pmRNSTransaction in Own Shares
5th Jan 20225:27 pmRNSTransaction in Own Shares
4th Jan 20225:32 pmRNSTransaction in Own Shares
23rd Dec 20215:22 pmRNSTransaction in Own Shares
22nd Dec 20215:40 pmRNSTransaction in Own Shares
21st Dec 20215:27 pmRNSTransaction in Own Shares
20th Dec 20215:55 pmRNSTransaction in Own Shares
17th Dec 20215:51 pmRNSTransaction in Own Shares
16th Dec 20215:55 pmRNSTransaction in Own Shares
15th Dec 20215:56 pmRNSTransaction in Own Shares
14th Dec 20215:38 pmRNSTransaction in Own Shares
14th Dec 20215:08 pmRNSLTIP awards; Director/PDMR Shareholding
13th Dec 20216:15 pmRNSTransaction in Own Shares
13th Dec 20217:00 amRNSTransaction in Own Shares
9th Dec 20215:47 pmRNSTransaction in Own Shares
8th Dec 20216:18 pmRNSTransaction in Own Shares
7th Dec 20215:46 pmRNSTransaction in Own Shares
6th Dec 20215:45 pmRNSTransaction in Own Shares
6th Dec 20211:56 pmRNSDirector/PDMR Shareholding
3rd Dec 20215:39 pmRNSTransaction in Own Shares
2nd Dec 20216:19 pmRNSTransaction in Own Shares
1st Dec 20216:07 pmRNSTransaction in Own Shares
1st Dec 20211:27 pmRNSChange of Registered Office
1st Dec 20217:00 amRNSTransaction in Own Shares
29th Nov 20215:32 pmRNSTransaction in Own Shares
29th Nov 20217:00 amRNSAdditional fair value gain of £27.4m
26th Nov 20215:39 pmRNSTransaction in Own Shares
26th Nov 20217:00 amRNSTransaction in Own Shares
24th Nov 20216:05 pmRNSTransaction in Own Shares
23rd Nov 20216:19 pmRNSTransaction in Own Shares
23rd Nov 20216:18 pmRNSPortfolio company ieso raises £39m
22nd Nov 20216:27 pmRNSTransaction in Own Shares
19th Nov 20215:41 pmRNSTransaction in Own Shares
18th Nov 20216:07 pmRNSTransaction in Own Shares
17th Nov 20215:43 pmRNSTransaction in Own Shares
17th Nov 20212:08 pmRNSPortfolio company Ultraleap raises £60 million
16th Nov 20215:46 pmRNSTransaction in Own Shares
15th Nov 20215:34 pmRNSTransaction in Own Shares
15th Nov 20217:00 amRNSTransaction in Own Shares
11th Nov 20216:11 pmRNSTransaction in Own Shares
11th Nov 20217:09 amRNSPortfolio company RFC Power signs JDA with Ceres
10th Nov 20216:22 pmRNSTransaction in Own Shares
9th Nov 20216:12 pmRNSTransaction in Own Shares
8th Nov 20216:11 pmRNSTransaction in Own Shares
5th Nov 20215:24 pmRNSTransaction in Own Shares

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.